314 related articles for article (PubMed ID: 31985912)
21. Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers.
Zane LT; Hughes MH; Shakib S
Am J Clin Dermatol; 2016 Oct; 17(5):519-526. PubMed ID: 27335049
[TBL] [Abstract][Full Text] [Related]
22. 2-Year animal carcinogenicity results for crisaborole, a novel phosphodiesterase 4 inhibitor for atopic dermatitis.
Ciaravino V; Coronado D; Lanphear C; Chanda S
J Dermatol Sci; 2017 Aug; 87(2):116-122. PubMed ID: 28416366
[TBL] [Abstract][Full Text] [Related]
23. Post Hoc Analyses of the Effect of Crisaborole Topical Ointment, 2% on Atopic Dermatitis: Associated Pruritus from Phase 1 and 2 Clinical Studies.
Draelos ZD; Stein Gold LF; Murrell DF; Hughes MH; Zane LT
J Drugs Dermatol; 2016 Feb; 15(2):172-6. PubMed ID: 26885784
[TBL] [Abstract][Full Text] [Related]
24. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
25. Soft drugs for dermatological applications: recent trends.
Aprile S; Serafini M; Pirali T
Drug Discov Today; 2019 Dec; 24(12):2234-2246. PubMed ID: 31494188
[TBL] [Abstract][Full Text] [Related]
26. Pharmacological management of atopic dermatitis in the elderly.
Howell AN; Ghamrawi RI; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2020 May; 21(7):761-771. PubMed ID: 32100586
[TBL] [Abstract][Full Text] [Related]
27. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
28. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
29. Crisaborole and its potential role in treating atopic dermatitis: overview of early clinical studies.
Zane LT; Chanda S; Jarnagin K; Nelson DB; Spelman L; Gold LS
Immunotherapy; 2016 Jul; 8(8):853-66. PubMed ID: 27283509
[TBL] [Abstract][Full Text] [Related]
30. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor.
Yosipovitch G; Gold LF; Lebwohl MG; Silverberg JI; Tallman AM; Zane LT
Acta Derm Venereol; 2018 Apr; 98(5):484-489. PubMed ID: 29363715
[TBL] [Abstract][Full Text] [Related]
31. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
[TBL] [Abstract][Full Text] [Related]
32. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
33. Impact of Crisaborole in Treatment-Experienced Patients With Mild-to-Moderate Atopic Dermatitis.
Stein Gold LF; Tom WL; Shi V; Sanders P; Zang C; Vlahos B; Cha A
Dermatitis; 2024; 35(1):84-91. PubMed ID: 38206678
[No Abstract] [Full Text] [Related]
34. Ex vivo (human skin) and in vivo (minipig) permeation of propylene glycol applied as topical crisaborole ointment, 2.
Thombre A; Tse S; Yeoh T; Chen R; North R; Brown M
Int J Pharm; 2020 Feb; 576():118847. PubMed ID: 31759994
[TBL] [Abstract][Full Text] [Related]
35. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis.
Castelli G; Schaffer M
Am Fam Physician; 2018 Sep; 98(6):379-380. PubMed ID: 30215912
[No Abstract] [Full Text] [Related]
36. Treatment of Skin Inflammation with Benzoxaborole Phosphodiesterase Inhibitors: Selectivity, Cellular Activity, and Effect on Cytokines Associated with Skin Inflammation and Skin Architecture Changes.
Dong C; Virtucio C; Zemska O; Baltazar G; Zhou Y; Baia D; Jones-Iatauro S; Sexton H; Martin S; Dee J; Mak Y; Meewan M; Rock F; Akama T; Jarnagin K
J Pharmacol Exp Ther; 2016 Sep; 358(3):413-22. PubMed ID: 27353073
[TBL] [Abstract][Full Text] [Related]
37. Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin.
Kim M; Del Duca E; Cheng J; Carroll B; Facheris P; Estrada Y; Cha A; Werth J; Bissonnette R; Nocka K; Zang C; Pavel AB; Guttman-Yassky E
J Am Acad Dermatol; 2023 Aug; 89(2):283-292. PubMed ID: 37054814
[TBL] [Abstract][Full Text] [Related]
38. 2% Crisaborole topical ointment for the treatment of mild-to-moderate atopic dermatitis.
Cheape AC; Murrell DF
Expert Rev Clin Immunol; 2017 May; 13(5):415-423. PubMed ID: 28290219
[TBL] [Abstract][Full Text] [Related]
39. Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis.
Simpson EL; Yosipovitch G; Bushmakin AG; Cappelleri JC; Luger T; Ständer S; Tom WL; Ports WC; Zielinski MA; Tallman AM; Tan H; Gerber RA
Acta Derm Venereol; 2019 Jul; 99(9):756-761. PubMed ID: 30896779
[TBL] [Abstract][Full Text] [Related]
40. Anti-inflammatory effects of a novel phosphodiesterase-4 inhibitor, AA6216, in mouse dermatitis models.
Kubota-Ishida N; Matsuhira T; Kaji C; Kikuchi C; Tabata Y
Eur J Pharmacol; 2021 Sep; 906():174258. PubMed ID: 34139195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]